Putnam FL Investment Management Co. Buys Shares of 56,811 C.R. Bard, Inc. (BCR)

Putnam FL Investment Management Co. acquired a new position in shares of C.R. Bard, Inc. (NYSE:BCR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 56,811 shares of the medical instruments supplier’s stock, valued at approximately $18,208,000. C.R. Bard comprises about 1.7% of Putnam FL Investment Management Co.’s investment portfolio, making the stock its 15th biggest position. Putnam FL Investment Management Co. owned about 0.08% of C.R. Bard as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BCR. Farallon Capital Management LLC acquired a new stake in shares of C.R. Bard during the second quarter worth $463,101,000. Alpine Associates Management Inc. acquired a new stake in shares of C.R. Bard during the second quarter worth $265,663,000. Pentwater Capital Management LP acquired a new stake in shares of C.R. Bard during the second quarter worth $139,088,000. York Capital Management Global Advisors LLC acquired a new stake in shares of C.R. Bard during the second quarter worth $122,678,000. Finally, CNH Partners LLC acquired a new stake in shares of C.R. Bard during the second quarter worth $116,100,000. Institutional investors and hedge funds own 78.27% of the company’s stock.

C.R. Bard, Inc. (BCR) traded down $1.08 during trading hours on Thursday, reaching $332.26. The company’s stock had a trading volume of 505,400 shares, compared to its average volume of 665,987. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. C.R. Bard, Inc. has a one year low of $206.26 and a one year high of $335.84. The stock has a market capitalization of $24,297.94, a price-to-earnings ratio of 28.79, a PEG ratio of 2.55 and a beta of 0.53.

C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. During the same period last year, the company posted $2.64 earnings per share. The firm’s revenue was up 5.1% compared to the same quarter last year. research analysts predict that C.R. Bard, Inc. will post 11.89 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.70%.

In other C.R. Bard news, VP Frank Lupisella, Jr. sold 9,173 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $325.00, for a total value of $2,981,225.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Sharon M. Luboff sold 30,252 shares of the firm’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $320.00, for a total value of $9,680,640.00. The disclosure for this sale can be found here. Insiders sold 191,593 shares of company stock worth $62,655,513 over the last three months. 0.80% of the stock is currently owned by corporate insiders.

BCR has been the topic of a number of research analyst reports. Cowen and Company reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a report on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. Jefferies Group LLC reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a report on Thursday, September 14th. Barclays PLC lifted their target price on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Finally, BidaskClub cut C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $303.50.

TRADEMARK VIOLATION NOTICE: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.themarketsdaily.com/2017/11/16/putnam-fl-investment-management-co-buys-shares-of-56811-c-r-bard-inc-bcr.html.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply